PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25971297-10	2015	Importantly, PF-04554878 synergized with the mTOR inhibitor everolimus by preventing feedback AKT activation.	defactinib	13-24	AKT serine/threonine kinase 1	Homo sapiens	94-97	
33283357-0	2021	Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.	defactinib	38-48	AKT serine/threonine kinase 1	Homo sapiens	174-177	
33283357-4	2021	Mechanistically, defactinib dose and time-dependently induced the dissociation of phosphoinositide-3-kinase (PI3K) from FAK, resultantly led to blockade of protein kinase B (AKT) signaling, and the expression of several oncogenes, such as SOX2, MYC, EGFR, MET, MDM2, or TGFBR2, identified by microarray and real-time polymerase chain reaction assay.	defactinib	17-27	AKT serine/threonine kinase 1	Homo sapiens	174-177